The estimated Net Worth of Arindam Bose is at least $195 Tisíc dollars as of 2 January 2024. Arindam Bose owns over 27,174 units of Dyadic International stock worth over $33,968 and over the last 5 years he sold DYAI stock worth over $0. In addition, he makes $161,500 as Independent Director at Dyadic International.
Sign up
Arindam Bose DYAI stock SEC Form 4 insiders trading
Arindam has made over 1 trades of the Dyadic International stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 27,174 units of DYAI stock worth $33,968 on 2 January 2024.
The largest trade he's ever made was exercising 27,174 units of Dyadic International stock on 2 January 2024 worth over $33,968. On average, Arindam trades about 3,882 units every 0 days since 2019. As of 2 January 2024 he still owns at least 27,174 units of Dyadic International stock.
You can see the complete history of Arindam Bose stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Arindam Bose biography
Dr. Arindam Bose Ph.D. serves as Independent Director of the Company. Arindam Bose, Ph.D. joined the Board on August 15, 2016 and serves on the Company’s Audit and Science and Technology Committees. Dr. Bose retired from Pfizer Worldwide Research & Development in 2016 after 34 years in leadership roles in bioprocess development and clinical manufacturing. Dr. Bose’s final position at Pfizer was Vice-President, Biotherapeutics Pharmaceutical Sciences External Affairs and Biosimilar Strategy with responsibility for external sourcing, competitive intelligence and external influencing as well as for executing the technical development plan for Pfizer’s entry into biosimilars. He is widely recognized as a Key Thought Leader in the biopharmaceutical industry. Dr. Bose has served as the Chair of the Biologics and Biotechnology Leadership Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA), the chief advocacy arm of the US pharmaceutical industry. His outstanding accomplishments and service to the profession have been recognized by his election as “Fellow” of 3 leading professional organizations: American Chemical Society, American Institute of Chemical Engineers and American Institute for Medical and Biological Engineering. Dr. Bose was elected to the US National Academy of Engineering in February 2017 for innovative research in biologics manufacturing. Dr. Bose currently provides consulting services in bioprocessing to several start-up biotechnology companies including a part-time process development management role at Akero Therapeutics (NASDAQ: AKRO). He received a Ph.D. in chemical engineering from Purdue University, a M.S. from the University of Michigan, Ann Arbor and a B. Tech from the Indian Institute of Technology, Kanpur.
What is the salary of Arindam Bose?
As the Independent Director of Dyadic International, the total compensation of Arindam Bose at Dyadic International is $161,500. There are 8 executives at Dyadic International getting paid more, with Mark Emalfarb having the highest compensation of $1,074,050.
How old is Arindam Bose?
Arindam Bose is 67, he's been the Independent Director of Dyadic International since 2016. There are 2 older and 9 younger executives at Dyadic International. The oldest executive at Dyadic International, Inc. is Jack Kaye, 76, who is the Independent Director.
What's Arindam Bose's mailing address?
Arindam's mailing address filed with the SEC is C/O DYADIC INTERNATIONAL, INC., 1044 NORTH U.S. HIGHWAY ONE, SUITE 201, JUPITER, FL, 33477-5094.
Insiders trading at Dyadic International
Over the last 6 years, insiders at Dyadic International have traded over $118,246,658,250 worth of Dyadic International stock and bought 27,000 units worth $100,230 . The most active insiders traders include Mark A Emalfarb, Ronen Tchelet a Seth Herbst. On average, Dyadic International executives and independent directors trade stock every 73 days with the average trade being worth of $54,365. The most recent stock trade was executed by Barry Buckland on 11 June 2024, trading 11,793 units of DYAI stock currently worth $18,751.
What does Dyadic International do?
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.
What does Dyadic International's logo look like?
Complete history of Arindam Bose stock trades at Dyadic International
Dyadic International executives and stock owners
Dyadic International executives and other stock owners filed with the SEC include:
-
Mark Emalfarb,
President, Chief Executive Officer, Director -
Mark A. Emalfarb,
Founder, CEO, Pres & Director -
Matthew Jones,
Managing Director - Business Development and Licensing -
Ping Rawson,
Chief Financial Officer, Chief Accounting Officer -
Matthew S. Jones,
Managing Director of Bus. Devel. & Licensing -
Ronen Tchelet,
Vice President of Research and Business Development -
Dr. Ronen Tchelet Ph.D.,
VP of Research & Bus. Devel. -
Jack Kaye,
Independent Director -
Arindam Bose,
Independent Director -
Michael Tarnok,
Independent Chairman of the Board -
Seth Herbst,
Independent Director -
Barry Buckland,
Independent Director -
Ana Gómez Rodriguez,
Sec. of the Board -
Joseph P. Hazelton,
Chief Bus. Officer -
Patrick K. Lucy,
Director -
Trust Under Agreement Dated...,
10% owner -
Joseph P Hazelton,
Chief Business Officer